Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Noile-Immune Biotech's Other Operating Expense for the
three
months ended in Dec. 2025 was 円0.00 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was 円0.00 Mil.
Noile-Immune Biotech's quarterly Other Operating Expense
stayed the same
from Jun. 2025 (円0.00 Mil) to Sep. 2025 (円0.00 Mil) and
stayed the same
from Sep. 2025 (円0.00 Mil) to Dec. 2025 (円0.00 Mil).
Noile-Immune Biotech's annual Other Operating Expense
increased
from Dec. 2023 (円-0.00 Mil) to Dec. 2024 (円0.00 Mil) but then
declined
from Dec. 2024 (円0.00 Mil) to Dec. 2025 (円0.00 Mil).
Noile-Immune Biotech Other Operating Expense Related Terms
Noile-Immune Biotech Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Noile-Immune Biotech's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Noile-Immune Biotech Other Operating Expense Chart
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of 円0.00 Mil mean?
Noile-Immune Biotech (TSE:4893) has a Other Operating Expense of 円0.00 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Noile-Immune Biotech and its competitors.
Is Noile-Immune Biotech's Other Operating Expense too high?
Noile-Immune Biotech's current Other Operating Expense is 円0.00 Mil. Overall, Noile-Immune Biotech has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noile-Immune Biotech's Other Operating Expense compare to VRTX and REGN?
Noile-Immune Biotech's Other Operating Expense of 円0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Noile-Immune Biotech and its competitors. Noile-Immune Biotech's current Other Operating Expense is 円0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noile-Immune Biotech stock overvalued right now?
Based on GuruFocus' analysis, Noile-Immune Biotech (TSE:4893) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.25, compared to a current price of 円141.00 — trading 3217.6% above its estimated fair value. The current Other Operating Expense is 円0.00 Mil. Noile-Immune Biotech's overall GF Score™ is 46/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Noile-Immune Biotech (TSE:4893), the current Other Operating Expense is 円0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Noile-Immune Biotech (TSE:4893) Overvalued in 2026?
Based on GuruFocus' analysis, Noile-Immune Biotech stock appears to be overvalued.
The current stock price of 円141.00 is trading 3217.6% above its estimated GF Value™ of 円4.25.
GuruFocus considers Noile-Immune Biotech to be Significantly Overvalued.
Key valuation signals for TSE:4893:
Other Operating Expense: 円0.00 Mil
GF Value™: 円4.25 vs. price of 円141.00 (3217.6% above fair value)
No single metric tells the full story. See the TSE:4893 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
46GF Score
Get the complete analysis for TSE:4893
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4893 has been successfully added to your 
